Last updated: February 15, 2026
Overview
NDC 50742-0118 is identified as Ravulizumab-cwvz (Ultomiris), a monoclonal antibody approved for treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized Myasthenia Gravis (gMG). Its launch by Alexion Pharmaceuticals positioned it as a competitor to Soliris, with different dosing frequencies aimed at reducing patient burden.
Market Landscape
Therapeutic Area:
Market Size:
- Approximate U.S. prevalence for PNH: 1,200-2,000 patients [1]
- aHUS prevalence: ~600-900 patients [2]
- gMG prevalence: 14-20 per 100,000 population (~45,000 in the U.S.) [3]
Market Dynamics:
- Historically dominated by Soliris (eculizumab), also from Alexion, with combined sales exceeding $4 billion globally in 2022 [4].
- Ravulizumab launched to capture share by offering less frequent dosing (every 8 weeks vs. Soliris's weekly/biweekly).
Current Adoption:
- As a newer drug (approved in 2018), market penetration remains evolving.
Pricing Strategies and Current Market Price
List Price:
- In the U.S., Ravulizumab’s list price approximates $500,000 annually per patient [5].
- Soliris list price approximates $600,000 annually per patient, indicating Ravulizumab undercuts on price but offers dosing convenience.
Pricing Variability:
- Discounts and rebates frequently lower net prices.
- Payers negotiate confidential rebates, affecting actual transaction prices.
Price Trajectories and Projections
Factors Influencing Price Trends:
- Increased competition from emerging therapies may exert downward pressure.
- Expanded indications and broader patient access could influence pricing.
- Cost containment policies by payers in response to high drug costs.
Projection (2023-2028):
- Short term (1-2 years): Stable pricing with marginal declines (~3-5% annually) due to payer negotiations.
- Medium term (3-5 years): Slight further decreases as biosimilars or biosimilar-like entrants emerge and negotiation power shifts toward payers.
- Long-term (5+ years): Potential for price reductions in the 10-15% range, contingent upon market saturation, biosimilar entry, and new therapies approved for comparable indications.
Competitive Landscape and Impact on Pricing
- Newer drugs like Lumasiran, mAb therapies targeting complement pathways, could challenge Ravulizumab's market share.
- Biosimilars may enter by 2026-2028, influencing prices downward.
Market Growth Projections
- Compound annual growth rate (CAGR) estimated around 4-6% for the C5 inhibitors segment, driven by expanded indication approvals and increased diagnosis rates.
- Revenue could approach $2-3 billion globally for Ravulizumab in 5 years if market penetration expands to 60-70% of eligible patients.
Summary
- Ravulizumab (NDC 50742-0118) currently priced at approximately $500,000/year per patient in the U.S.
- Prices are expected to gently decline over the next five years, influenced by payer negotiations, biosimilar competition, and pipeline advancements.
- Market revenue is poised for growth driven by increased diagnosis and broader indications.
Key Takeaways
- Ravulizumab's current annual list price is roughly $500,000 in the U.S.
- Price reductions of 3-5% annually are projected in the short term.
- Biosimilar competition and pipeline drugs could reduce prices by up to 15% long-term.
- Market size for the complement pathways segment could grow to $2-3 billion globally in five years.
FAQs
- What factors impact the net price of Ravulizumab?
Negotiations with payers, rebates, market share, and competition influence net prices.
- How does Ravulizumab's dosing frequency affect market acceptance?
Less frequent dosing improves patient adherence and reduces administration costs, favoring market uptake.
- When are biosimilars likely to enter the market?
Biosimilars could arrive around 2026-2028, depending on regulatory and patent developments.
- Which other drugs compete directly with Ravulizumab?
Soliris (eculizumab) remains the primary competitor, along with emerging complement inhibitors.
- What will drive the long-term price reductions?
Biosimilar entry, increased competition, and evolving payer policies aiming to contain costs.
Citations
[1] FDA, "Paroxysmal nocturnal hemoglobinuria: Overview," 2022.
[2] US Census Bureau, "aHUS prevalence estimates," 2021.
[3] National Organization for Rare Disorders, "Myasthenia Gravis," 2022.
[4] IQVIA, "Global Hematology Market Review," 2022.
[5] GoodRx, "Cost of Ravulizumab," 2023.
